Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/22/2017
LabCorp
mi
from
Redmond, WA
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/22/2017
LabCorp
mi
from
Redmond, WA
Click here to add this to my saved trials
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
Safety of Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma: A Pilot Study
Status: Enrolling
Updated:  5/22/2017
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
Safety of Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma: A Pilot Study
Status: Enrolling
Updated: 5/22/2017
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
Safety of Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma: A Pilot Study
Status: Enrolling
Updated:  5/22/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
Safety of Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma: A Pilot Study
Status: Enrolling
Updated: 5/22/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy
Status: Enrolling
Updated:  5/23/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy
Status: Enrolling
Updated: 5/23/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Clackamas Radiation Oncology Center
mi
from
Clackamas, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Clackamas Radiation Oncology Center
mi
from
Clackamas, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Newberg Medical Center
mi
from
Newberg, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Newberg Medical Center
mi
from
Newberg, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Willamette Falls Medical Center
mi
from
Oregon City, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Willamette Falls Medical Center
mi
from
Oregon City, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Portland Medical Center
mi
from
Portland, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Oregon Health and Science University
mi
from
Portland, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  5/23/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 5/23/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  5/23/2017
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 5/23/2017
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  5/23/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 5/23/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  5/23/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 5/23/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  5/23/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 5/23/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  5/23/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 5/23/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  5/23/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 5/23/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated:  5/23/2017
MedStar Georgetown University Hospital
mi
from
Washington, D.C.,
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Status: Enrolling
Updated: 5/23/2017
MedStar Georgetown University Hospital
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Navigator Guided e-Psychoeducational Intervention
Navigator Guided e-Psychoeducational Intervention for Prostate Cancer Patients and Their Caregivers
Status: Enrolling
Updated:  5/23/2017
H. Lee Moffitt Cancer and Research Institute
mi
from
Tampa, FL
Navigator Guided e-Psychoeducational Intervention
Navigator Guided e-Psychoeducational Intervention for Prostate Cancer Patients and Their Caregivers
Status: Enrolling
Updated: 5/23/2017
H. Lee Moffitt Cancer and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  5/23/2017
Clinical Research Facility
mi
from
Sarasota, FL
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 5/23/2017
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  5/23/2017
MSD Belgium BVBA/SPRL
mi
from
Brussels,
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 5/23/2017
MSD Belgium BVBA/SPRL
mi
from
Brussels,
Click here to add this to my saved trials
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  5/23/2017
Clinical Research Facility
mi
from
Boston, MA
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 5/23/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  5/23/2017
Clinical Research Facility
mi
from
Philadelphia, PA
A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 5/23/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
St. Joseph Hospital of Orange
mi
from
Orange, CA
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
St. Joseph Hospital of Orange
mi
from
Orange, CA
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
The Hartford Hospital
mi
from
Hartford, CT
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
Christiana Care Health Services
mi
from
Wilmington, DE
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
Christiana Care Health Services
mi
from
Wilmington, DE
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
The Cancer Program of Our Lady of the Lake and Mary Bird Perkins
mi
from
Baton Rouge, LA
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
The Cancer Program of Our Lady of the Lake and Mary Bird Perkins
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
The Mayo Clinic
mi
from
Rochester, MN
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
Memorial Sloan-Kettering Cancer
mi
from
New York, NY
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
Memorial Sloan-Kettering Cancer
mi
from
New York, NY
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
Gibbs Cancer Center
mi
from
Spartanburg, SC
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
Gibbs Cancer Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated:  5/23/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Status: Enrolling
Updated: 5/23/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
2 Phase Use Of Educational Materials In Head And Neck Cancer Center
A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center
Status: Enrolling
Updated:  5/24/2017
Massachusetts General Hospital
mi
from
Boston, MA
2 Phase Use Of Educational Materials In Head And Neck Cancer Center
A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center
Status: Enrolling
Updated: 5/24/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Interleukin-2—Induced Cognitive/Affective/Sleep Symptoms
Investigating Cognitive/Affective/Sleep Symptoms During High-dose Interleukin-2 Therapy
Status: Enrolling
Updated:  5/30/2017
Duke University Hospital
mi
from
Durham, NC
Interleukin-2—Induced Cognitive/Affective/Sleep Symptoms
Investigating Cognitive/Affective/Sleep Symptoms During High-dose Interleukin-2 Therapy
Status: Enrolling
Updated: 5/30/2017
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Phoenix, AZ
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Little Rock, AR
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated:  5/30/2017
GSK Investigational Site
mi
from
Bakersfield, CA
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Status: Enrolling
Updated: 5/30/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials